Gene Therapy In Oncology Market Research Report- Ken Research
Buy Now Gene Therapy Overview Gene therapy combines reduced treatment duration with a higher chance of cure unlike conventional oncology treatments such as chemotherapy. However this novel therapeutic approach requires the delivery of genetic material to the patient, an uncharted territory in oncology which will necessitate the implementation of new regulatory guidelines and the restructuring of existing treatment algorithms in various oncology indications. The current clinical development of gene therapies in oncology is dominated by small size biotech and pharmaceutical companies. Astrazeneca is the only large pharmaceutical company with an in-house gene therapy in late stage clinical development. Other major players such as johnson & johnson have the exclusive worldwide rights to develop and commercialize geron’s imetelstat, while merck & co. And bms are evaluating their respective checkpoint inhibitor therapies with many of the phase iii and phase i...